Table A-7Drug Effectiveness Review Project (2001)

Overall Standards/Policies
 An investigator or staff member working on a project must state that he/she has no financial interests in any pharmaceutical company. The assurance of an absence of conflicts of interest related to financial interests in pharmaceutical companies is declared annually for any investigator or staff member continuing to work with DERP.
Definitions and Examples
 Financial interestsCurrent direct ownership of stock of a pharmaceutical company (does not include ownership of mutual funds that may partly include pharmaceutical company stock); current research funding received from a pharmaceutical company; current membership on a speaker’s bureau of a pharmaceutical company; consulting fees or honoraria accepted from a pharmaceutical company during the project period.

Source: Oregon Evidence-based Practice Center. Policy on Conflicts of Interest re: Work on the Drug Effectiveness Review Project. Oregon Evidence-based Practice Center; 2001.

From: Appendix A, Institutional Standards and Definitions for Managing Conflicts of Interest

Cover of Identifying and Managing Nonfinancial Conflicts of Interest for Systematic Reviews
Identifying and Managing Nonfinancial Conflicts of Interest for Systematic Reviews [Internet].
Viswanathan M, Carey TS, Belinson SE, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.